Who
C. David Nicholson
Director
Company insider
Files Form 4 as: Director, Actinium Pharmaceuticals, Inc. (Delaware); Director, Adverum Biotechnologies.
In numbers
- Trades disclosed
- 27
- Buys
- 1
- Sells
- 0
- Bought
- $10K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 14 Apr 2016
- Last trade
- 2 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 4 Sep 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Code A | —62,800 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —94,200 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —94,200 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Code A | —62,800 at $0.00 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —8,000 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —10,520 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —10,450 | filing |
| 17 Jun 2025filed 20 Jun 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code A | —10,450 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —2,500 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —2,500 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —2,500 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —8,333 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —8,333 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —18,351 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —72,156 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —70,311 at $0.00 | filing |
| 17 Jun 2024filed 20 Jun 2024 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code A | —10,520 at $0.00 | filing |
| 28 Dec 2023filed 29 Dec 2023 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —70,311 at $0.00 | filing |
| 3 Nov 2023filed 6 Nov 2023 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 1 Jul 2022filed 1 Jul 2022 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —72,156 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.